Vasundhara Rasayans Ltd Stock Falls to 52-Week Low of Rs 120

3 hours ago
share
Share Via
Vasundhara Rasayans Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.120 today, marking a significant decline amid a series of consecutive losses. The stock has underperformed both its sector and broader market indices, reflecting ongoing pressures on its financial performance and valuation metrics.
Vasundhara Rasayans Ltd Stock Falls to 52-Week Low of Rs 120

Recent Price Movement and Market Context

On 4 March 2026, Vasundhara Rasayans Ltd opened with a gap down of -2.22%, continuing a four-day losing streak that has resulted in an 8.47% decline over this period. The stock’s intraday low of Rs.120 represents a 4.99% drop on the day and sets a fresh 52-week low. This performance contrasts with the broader market, where the Sensex, despite opening sharply lower by 1,710.03 points, managed a partial recovery to trade at 78,860.11, down 1.72% overall. The stock also underperformed its sector by 3.96% on the day.

Vasundhara Rasayans is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum. This technical positioning underscores the stock’s ongoing weakness relative to both short-term and long-term trends.

Strong fundamentals, solid momentum, fair price – This Large Cap from the NBFC sector checks every box for our Top 1%. This should definitely be on your radar!

  • - Complete fundamentals package
  • - Technical momentum confirmed
  • - Reasonable valuation entry

Add to Your Radar Now →

Long-Term Performance and Financial Metrics

Over the past year, Vasundhara Rasayans Ltd has delivered a total return of -46.44%, markedly underperforming the Sensex, which posted an 8.04% gain over the same period. The stock’s 52-week high was Rs.289, highlighting the extent of the decline from its peak levels.

The company’s financial performance has also shown signs of deterioration. Operating profits have contracted at a compound annual growth rate (CAGR) of -6.46% over the last five years, indicating challenges in sustaining profitability. The latest quarterly results reveal a profit before tax (PBT) of Rs.0.30 crore, down 63.2% compared to the average of the previous four quarters. Similarly, the quarterly profit after tax (PAT) stood at Rs.0.72 crore, a decline of 36.4% relative to the prior four-quarter average. Net sales for the quarter were Rs.7.45 crore, the lowest recorded in recent periods.

These figures reflect a subdued near-term performance alongside a longer-term trend of declining profitability. The stock’s underperformance extends beyond the last year, with returns lagging the BSE500 index over one, three years, and the past three months.

Valuation and Shareholding Structure

Despite the recent price weakness, Vasundhara Rasayans maintains a price-to-book value ratio of 1.1, suggesting a fair valuation relative to its book value. The company’s return on equity (ROE) stands at 10.7%, which is moderate within the Pharmaceuticals & Biotechnology sector. However, the stock trades at a premium compared to the average historical valuations of its peers, indicating that the market may be pricing in expectations that have yet to materialise.

The majority shareholding is held by promoters, which often implies a stable ownership structure. However, this has not translated into positive momentum for the stock in recent times.

Sector and Market Comparison

Within the Pharmaceuticals & Biotechnology sector, Vasundhara Rasayans’ performance contrasts with broader sector trends. While the sector has faced some headwinds, the stock’s underperformance relative to its peers and the overall market is notable. Additionally, other indices such as NIFTY Realty and S&P BSE Realty also hit new 52-week lows on the same day, reflecting selective weakness in certain segments of the market.

The Sensex’s technical indicators show it trading below its 50-day moving average, though the 50-day average remains above the 200-day average, signalling a mixed medium-term outlook for the broader market.

Holding Vasundhara Rasayans Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!

  • - Peer comparison ready
  • - Superior options identified
  • - Cross market-cap analysis

Switch to Better Options →

Mojo Score and Rating Update

Vasundhara Rasayans Ltd currently holds a Mojo Score of 12.0, which corresponds to a Strong Sell rating. This represents a downgrade from its previous Sell grade, effective from 17 December 2025. The Market Cap Grade is rated at 4, reflecting the company’s relatively modest market capitalisation within its sector.

The downgrade to Strong Sell is driven by the company’s weak long-term fundamental strength, deteriorating profitability metrics, and sustained price weakness. These factors collectively contribute to the cautious stance reflected in the Mojo grading system.

Summary of Key Financial and Market Indicators

To summarise, Vasundhara Rasayans Ltd’s key metrics as of 4 March 2026 are:

  • New 52-week low price: Rs.120
  • One-year return: -46.44%
  • Operating profit CAGR (5 years): -6.46%
  • Latest quarterly PBT: Rs.0.30 crore (-63.2% vs previous 4Q average)
  • Latest quarterly PAT: Rs.0.72 crore (-36.4% vs previous 4Q average)
  • Net sales (quarterly): Rs.7.45 crore (lowest recent level)
  • Price-to-book value: 1.1
  • Return on equity: 10.7%
  • Mojo Score: 12.0 (Strong Sell)

The stock’s performance and financial indicators highlight a period of sustained pressure, with valuation and profitability metrics reflecting the challenges faced by the company in recent quarters.

Technical and Market Sentiment Considerations

Technically, the stock’s position below all major moving averages signals continued downward momentum. The four-day consecutive decline and the gap down opening today reinforce the prevailing negative trend. While the broader market has shown some resilience, Vasundhara Rasayans has lagged behind both sector peers and the wider indices.

Investors and market participants will note the divergence between the stock’s performance and the partial recovery seen in the Sensex, underscoring the stock-specific factors influencing Vasundhara Rasayans’ price action.

Conclusion

Vasundhara Rasayans Ltd’s fall to a new 52-week low of Rs.120 marks a significant milestone in its recent price trajectory. The stock’s underperformance relative to the sector and broader market, combined with weakening financial results and a downgraded rating, reflect ongoing challenges. The company’s valuation remains fair but is accompanied by a premium relative to peers, while profitability metrics continue to trend lower. These factors collectively provide a comprehensive view of the stock’s current standing within the Pharmaceuticals & Biotechnology sector.

{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News